Michael W. Sill, Ph.D.
Affiliations: | 2000 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
StatisticsGoogle:
"Michael Sill"Parents
Sign in to add mentor| Allan R. Sampson | grad student | 2000 | University of Pittsburgh | |
| (Estimation and inference for drop-the-losers designs.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Eskander RN, Sill MW, Beffa L, et al. (2023) Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England Journal of Medicine |
| Tewari KS, Sill MW, Birrer MJ, et al. (2023) Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study. Gynecologic Oncology. 171: 141-150 |
| Tewari KS, Sill MW, Monk BJ, et al. (2020) . Molecular Cancer Therapeutics |
| Tewari KS, Sill MW, Coleman RL, et al. (2020) Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecologic Oncology |
| Zamarin D, Burger RA, Sill MW, et al. (2020) Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902059 |
| Chase D, Huang HQ, Monk BJ, et al. (2020) Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society |
| Westin SN, Sill MW, Coleman RL, et al. (2019) Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecologic Oncology |
| Matulonis UA, Sill MW, Makker V, et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology |
| Tew WP, Sill MW, Walker JL, et al. (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology |
| Richardson DL, Coleman RL, Sill MW. (2018) Paclitaxel and Pazopanib in Ovarian Cancer-Reply. Jama Oncology |